Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-15

Clinical Trial Update: Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating empagliflozin added to linagliptin in Japanese adults with type 2 diabetes has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin (empagliflozin)
  • Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2019-02-15